FDA Moves to Remove GLP-1 Weight Loss Drugs from Compounding List

The FDA proposed on April 30, 2026, to exclude semaglutide, tirzepatide, and liraglutide from the list of substances that 503B compounding facilities can use to make large quantities of medicines, determining there is no clinical need for compounded versions now that Novo Nordisk and Eli Lilly have adequate supplies. The decision affects ingredients in popular treatments including Wegovy, Ozempic, Mounjaro, and Zepbound, marking a victory for the pharmaceutical manufacturers while reworking consumer choices. The move ends years of growing controversy over large compounding facilities' role in making weight loss treatments available, as the FDA concluded these facilities no longer meet legal requirements to market their products. The decision will force patients currently using more affordable compounded versions to switch to higher-priced branded drugs or potentially lose access to GLP-1 treatments entirely.

FDA's Proposal to Remove GLP-1 Drugs from Compounding List

• ▪Tirzepatide is the ingredient in Eli Lilly's Zepbound obesity medicine.
• ▪The Food and Drug Administration decision singled out 503B facilities, which are large compounding facilities in regulatory parlance.
• ▪Semaglutide is the ingredient in Novo Nordisk's Ozempic diabetes treatment.
• ▪The Food and Drug Administration proposal was published on April 30, 2026.
• ▪Semaglutide is the ingredient in Novo Nordisk's Wegovy weight loss treatment.
• ▪The Food and Drug Administration proposed excluding the active ingredients in obesity and diabetes drugs from a list of substances that can be used for making certain compounded versions.
• ▪The Food and Drug Administration explained that 503B compounding facilities no longer meet the legal requirements to market their products.
• ▪Tirzepatide is the ingredient in Eli Lilly's Mounjaro diabetes drug.
• ▪The Food and Drug Administration determined there is no clinical need to allow large compounding facilities to make large quantities of medicines from semaglutide.

Impact on Pharmaceutical Companies and Consumer Access

• ▪The Food and Drug Administration decision to exclude GLP-1 drug ingredients from compounding is a victory for Novo Nordisk.
• ▪There has been growing controversy over 503B compounding facilities' role in making weight loss treatments available over the past few years.

Perspective of 503B compounding facilities

• ▪503B compounding facilities argue they have expanded access to GLP-1 treatments for patients who cannot afford branded versions.
• ▪The FDA's removal of semaglutide and tirzepatide from the compounding list threatens the business model of 503B facilities producing these drugs.
• ▪503B compounding facilities have been providing more affordable alternatives to brand-name GLP-1 weight loss drugs.

Perspective of Novo Nordisk and Eli Lilly

• ▪Novo Nordisk and Eli Lilly maintain they have resolved supply shortages that previously justified compounding exemptions.
• ▪Novo Nordisk and Eli Lilly have argued that compounded versions of their GLP-1 drugs pose safety and quality concerns.
• ▪The FDA's exclusion of GLP-1 ingredients from compounding restores market control to Novo Nordisk and Eli Lilly.

Perspective of Patients and consumers

• ▪The FDA decision limits consumer choice in GLP-1 weight loss and diabetes treatments.
• ▪Some patients may lose access to GLP-1 treatments entirely due to the higher cost of branded Wegovy, Ozempic, Mounjaro, and Zepbound.
• ▪Patients who have been using compounded semaglutide and tirzepatide will need to switch to more expensive branded versions.

1 source